The effects of donepezil in Alzheimer's disease - results from a multinational trial
- PMID: 10325453
- DOI: 10.1159/000017126
The effects of donepezil in Alzheimer's disease - results from a multinational trial
Abstract
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD). The current trial was undertaken to investigate further the efficacy and safety of donepezil, in a multinational setting, in patients with mild to moderately severe AD. This 30-week, placebo-controlled, parallel-group study consisted of a 24-week, double-blind treatment phase followed by a 6-week, single-blind, placebo washout. Eight hundred and eighteen patients with mild to moderately severe AD were randomly allocated to treatment with single, daily doses of 5 or 10 mg donepezil, or placebo. The two primary efficacy measures were: a cognitive performance test, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and a global evaluation, the Clinician's Interview-Based Impression of Change with caregiver input (CIBIC plus). Secondary outcome measures included the Sum of the Boxes of the Clinical Dementia Rating Scale (CDR-SB), a modified Interview for Deterioration in Daily living activities in Dementia (IDDD) and a patient rated quality of life assessment. Statistically significant improvements in cognitive and global function were observed, as evaluated by ADAS-cog and CIBIC plus, respectively, in both the 5 and 10 mg/day donepezil groups, compared with placebo. Treatment-associated changes were also observed in functional skills, as shown by improved scores on the CDR-SB and the complex-tasks component of the IDDD. A dose-response effect was evident, with the 10 mg/day donepezil group demonstrating greater benefits in all outcome measures than the 5 mg/day group. Donepezil was well tolerated by this patient population and did not produce any clinically significant laboratory test abnormalities. The results of this study confirm that donepezil is effective and well tolerated in treating the symptoms of mild to moderately severe AD.
Similar articles
-
Donepezil for vascular cognitive impairment.Cochrane Database Syst Rev. 2004;(1):CD004395. doi: 10.1002/14651858.CD004395.pub2. Cochrane Database Syst Rev. 2004. PMID: 14974068 Review.
-
Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.Dement Geriatr Cogn Disord. 2000 Nov-Dec;11(6):299-313. doi: 10.1159/000017259. Dement Geriatr Cogn Disord. 2000. PMID: 11044775 Clinical Trial.
-
Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. doi: 10.1159/000051201. Dement Geriatr Cogn Disord. 1998. PMID: 9853200 Review.
-
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.Arch Intern Med. 1998 May 11;158(9):1021-31. doi: 10.1001/archinte.158.9.1021. Arch Intern Med. 1998. PMID: 9588436 Clinical Trial.
-
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.Neurology. 1998 Jan;50(1):136-45. doi: 10.1212/wnl.50.1.136. Neurology. 1998. PMID: 9443470 Clinical Trial.
Cited by
-
Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease.Int J Mol Sci. 2024 May 9;25(10):5169. doi: 10.3390/ijms25105169. Int J Mol Sci. 2024. PMID: 38791206 Free PMC article. Review.
-
MST1 selective inhibitor Xmu-mp-1 ameliorates neuropathological changes in a rat model of sporadic Alzheimer's Disease by modulating Hippo-Wnt signaling crosstalk.Apoptosis. 2024 May 17. doi: 10.1007/s10495-024-01975-0. Online ahead of print. Apoptosis. 2024. PMID: 38760516
-
Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review.Medicine (Baltimore). 2024 Apr 19;103(16):e37799. doi: 10.1097/MD.0000000000037799. Medicine (Baltimore). 2024. PMID: 38640313 Free PMC article.
-
Shortening the Alzheimer's disease assessment scale cognitive subscale.Eur Psychiatry. 2024 Feb 23;67(1):e19. doi: 10.1192/j.eurpsy.2024.14. Eur Psychiatry. 2024. PMID: 38389390 Free PMC article.
-
Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies.Front Neurol. 2023 Oct 23;14:1241339. doi: 10.3389/fneur.2023.1241339. eCollection 2023. Front Neurol. 2023. PMID: 37936917 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical